Brought to you by 
Mylan and Agila divest 11 drugs ahead of acquisition
18 Nov 2022
Executive Summary
To satisfy anti-competitive conditions related to Mylan Inc.'s pending acquisition of Strides Arcolab Ltd.’s Agila Specialties Pvt. Ltd., the FTC is requiring the companies to divest 11 generic injectables to four different firms.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Product Purchase
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Mylan and Agila divest 11 drugs ahead of acquisition
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice